These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 26392164)
21. Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria. Miranda AS; Brant F; Rocha NP; Cisalpino D; Rodrigues DH; Souza DG; Machado FS; Rachid MA; Teixeira AL; Campos AC Malar J; 2013 Nov; 12():388. PubMed ID: 24180288 [TBL] [Abstract][Full Text] [Related]
22. Effects of the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor SU5416 on in vitro cultures of Plasmodium falciparum. Hempel C; Hoyer N; Staalsø T; Kurtzhals JA Malar J; 2014 May; 13():201. PubMed ID: 24885283 [TBL] [Abstract][Full Text] [Related]
23. PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria. Serghides L; McDonald CR; Lu Z; Friedel M; Cui C; Ho KT; Mount HT; Sled JG; Kain KC PLoS Pathog; 2014 Mar; 10(3):e1003980. PubMed ID: 24603727 [TBL] [Abstract][Full Text] [Related]
24. Pathogenic CD8 Pham TT; Verheijen M; Vandermosten L; Deroost K; Knoops S; Van den Eynde K; Boon L; Janse CJ; Opdenakker G; Van den Steen PE Front Cell Infect Microbiol; 2017; 7():416. PubMed ID: 29034214 [TBL] [Abstract][Full Text] [Related]
25. Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria. Val CH; Brant F; Miranda AS; Rodrigues FG; Oliveira BC; Santos EA; Assis DR; Esper L; Silva BC; Rachid MA; Tanowitz HB; Teixeira AL; Teixeira MM; Régis WC; Machado FS Malar J; 2015 Aug; 14():311. PubMed ID: 26260055 [TBL] [Abstract][Full Text] [Related]
27. Oral Therapy Using a Combination of Nanotized Antimalarials and Immunomodulatory Molecules Reduces Inflammation and Prevents Parasite Induced Pathology in the Brain and Spleen of Mukherjee S; Ray G; Saha B; Kar SK Front Immunol; 2021; 12():819469. PubMed ID: 35095923 [TBL] [Abstract][Full Text] [Related]
28. Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA. Palomo J; Fauconnier M; Coquard L; Gilles M; Meme S; Szeremeta F; Fick L; Franetich JF; Jacobs M; Togbe D; Beloeil JC; Mazier D; Ryffel B; Quesniaux VF Eur J Immunol; 2013 Oct; 43(10):2683-95. PubMed ID: 23780878 [TBL] [Abstract][Full Text] [Related]
29. Schistosoma co-infection protects against brain pathology but does not prevent severe disease and death in a murine model of cerebral malaria. Bucher K; Dietz K; Lackner P; Pasche B; Fendel R; Mordmüller B; Ben-Smith A; Hoffmann WH Int J Parasitol; 2011 Jan; 41(1):21-31. PubMed ID: 20708623 [TBL] [Abstract][Full Text] [Related]
30. Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice. Neill AL; Hunt NH Parasitology; 1992 Oct; 105 ( Pt 2)():165-75. PubMed ID: 1280805 [TBL] [Abstract][Full Text] [Related]
31. Rocaglates as dual-targeting agents for experimental cerebral malaria. Langlais D; Cencic R; Moradin N; Kennedy JM; Ayi K; Brown LE; Crandall I; Tarry MJ; Schmeing M; Kain KC; Porco JA; Pelletier J; Gros P Proc Natl Acad Sci U S A; 2018 Mar; 115(10):E2366-E2375. PubMed ID: 29463745 [TBL] [Abstract][Full Text] [Related]
32. Anxiety-like behavior and proinflammatory cytokine levels in the brain of C57BL/6 mice infected with Plasmodium berghei (strain ANKA). de Miranda AS; Lacerda-Queiroz N; de Carvalho Vilela M; Rodrigues DH; Rachid MA; Quevedo J; Teixeira AL Neurosci Lett; 2011 Mar; 491(3):202-6. PubMed ID: 21256928 [TBL] [Abstract][Full Text] [Related]
33. Investigation of hydrogen sulfide gas as a treatment against P. falciparum, murine cerebral malaria, and the importance of thiolation state in the development of cerebral malaria. DellaValle B; Staalsoe T; Kurtzhals JA; Hempel C PLoS One; 2013; 8(3):e59271. PubMed ID: 23555646 [TBL] [Abstract][Full Text] [Related]
35. Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria. Zhu X; Pan Y; Li Y; Jiang Y; Shang H; Gowda DC; Cui L; Cao Y Int Immunopharmacol; 2012 Aug; 13(4):392-7. PubMed ID: 22659438 [TBL] [Abstract][Full Text] [Related]
36. Plasmodium berghei: cerebral malaria in CBA mice is not clearly related to plasma TNF levels or intensity of histopathological changes. Carvalho LJ; Lenzi HL; Pelajo-Machado M; Oliveira DN; Daniel-Ribeiro CT; Ferreira-da-Cruz MF Exp Parasitol; 2000 May; 95(1):1-7. PubMed ID: 10864512 [TBL] [Abstract][Full Text] [Related]
37. Tamoxifen activity against Plasmodium in vitro and in mice. Weinstock A; Gallego-Delgado J; Gomes C; Sherman J; Nikain C; Gonzalez S; Fisher E; Rodriguez A Malar J; 2019 Nov; 18(1):378. PubMed ID: 31775753 [TBL] [Abstract][Full Text] [Related]
38. Role of IL-10-producing regulatory B cells in control of cerebral malaria in Plasmodium berghei infected mice. Liu Y; Chen Y; Li Z; Han Y; Sun Y; Wang Q; Liu B; Su Z Eur J Immunol; 2013 Nov; 43(11):2907-18. PubMed ID: 23893352 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of platelet adherence to brain microvasculature protects against severe Plasmodium berghei malaria. Sun G; Chang WL; Li J; Berney SM; Kimpel D; van der Heyde HC Infect Immun; 2003 Nov; 71(11):6553-61. PubMed ID: 14573677 [TBL] [Abstract][Full Text] [Related]
40. Platelet-activating factor receptor is essential for the development of experimental cerebral malaria. Lacerda-Queiroz N; Rodrigues DH; Vilela MC; Rachid MA; Soriani FM; Sousa LP; Campos RD; Quesniaux VF; Teixeira MM; Teixeira AL Am J Pathol; 2012 Jan; 180(1):246-55. PubMed ID: 22079430 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]